ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bristol Myers faces $6.4bn lawsuit over cancer drug delay
June 07, 2021UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR) -
USFDA extends review of Bristol Myers’ cancer therapy acquired in Celgene deal
May 07, 2020The company said it had submitted additional information on the therapy known as liso-cel, which was considered a major amendment to the marketing application by the agency. -
Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial
December 11, 2019Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.
Pharma Sources Insight January 2025
